002773 康弘药业
已收盘 06-17 15:00:00
资讯
新帖
简况
康弘药业:盐酸文拉法辛缓释片用于治疗抑郁症(包括伴有焦虑的抑郁症)及广泛性焦虑障碍
证券之星 · 06-13
康弘药业:盐酸文拉法辛缓释片用于治疗抑郁症(包括伴有焦虑的抑郁症)及广泛性焦虑障碍
康弘药业(002773)6月6日主力资金净买入1206.87万元
证券之星 · 06-07
康弘药业(002773)6月6日主力资金净买入1206.87万元
康弘药业:我司KH737由于整体项目规划,目前暂无启动临床研究的计划
证券之星 · 06-04
康弘药业:我司KH737由于整体项目规划,目前暂无启动临床研究的计划
康弘药业(002773.SZ):普拉洛芬滴眼液获药品注册证书
智通财经 · 06-03
康弘药业(002773.SZ):普拉洛芬滴眼液获药品注册证书
康弘药业最新公告:普拉洛芬滴眼液获得药品注册证书
证券之星 · 06-03
康弘药业最新公告:普拉洛芬滴眼液获得药品注册证书
康弘药业:截至2024年5月31日,公司股东户数为35,338户
证券之星 · 06-03
康弘药业:截至2024年5月31日,公司股东户数为35,338户
康弘药业:截至目前,公司尚未收到题述相关的股东动议
证券之星 · 05-30
康弘药业:截至目前,公司尚未收到题述相关的股东动议
康弘药业(002773.SZ)2023年拟每10股派3.8元 5月28日除权除息
智通财经 · 05-21
康弘药业(002773.SZ)2023年拟每10股派3.8元 5月28日除权除息
华福证券:给予康弘药业买入评级
证券之星 · 05-19
华福证券:给予康弘药业买入评级
康弘药业(002773)5月16日主力资金净卖出4518.99万元
证券之星 · 05-17
康弘药业(002773)5月16日主力资金净卖出4518.99万元
康弘药业(002773)5月15日主力资金净卖出6326.59万元
证券之星 · 05-16
康弘药业(002773)5月15日主力资金净卖出6326.59万元
康弘药业:我司立他司特滴眼液正在CDE审评审批,目前审评状态正常
证券之星 · 05-14
康弘药业:我司立他司特滴眼液正在CDE审评审批,目前审评状态正常
康弘药业:公司管理层在日常经营管理中,严控信用风险,勤勉尽责
证券之星 · 05-09
康弘药业:公司管理层在日常经营管理中,严控信用风险,勤勉尽责
康弘药业(002773)5月7日主力资金净买入3552.57万元
证券之星 · 05-08
康弘药业(002773)5月7日主力资金净买入3552.57万元
康弘药业:截至2024年4月30日,公司股东户数为39,839户
证券之星 · 05-06
康弘药业:截至2024年4月30日,公司股东户数为39,839户
康弘药业(002773.SZ):KH658眼用注射液在美临床试验获美国食品药品管理局批准
智通财经网 · 04-29
康弘药业(002773.SZ):KH658眼用注射液在美临床试验获美国食品药品管理局批准
康弘药业(002773.SZ):KH658眼用注射液临床试验获批
智通财经 · 04-29
康弘药业(002773.SZ):KH658眼用注射液临床试验获批
非酒精性脂肪性肝炎(NASH)概念盘中拉升,康弘药业涨3.92%
自选股智能写手 · 04-26
非酒精性脂肪性肝炎(NASH)概念盘中拉升,康弘药业涨3.92%
4月25日康弘药业连续2日创60日新高,万家中证1000指数增强A基金重仓该股
证券之星 · 04-25
4月25日康弘药业连续2日创60日新高,万家中证1000指数增强A基金重仓该股
4月25日康弘药业涨停分析:眼科,合成生物,创新药概念热股
证券之星 · 04-25
4月25日康弘药业涨停分析:眼科,合成生物,创新药概念热股
加载更多
公司概况
公司名称:
成都康弘药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2015-06-26
主营业务:
成都康弘药业集团股份有限公司主营业务为药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司目前上市产品主要为康柏西普眼用注射液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、右佐匹克隆片等药品和医疗器械。
发行价格:
13.62
{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":22.93,"timestamp":1718607816000,"preClose":22.39,"halted":0,"volume":7998727,"delay":0,"floatShares":685000000,"shares":919000000,"eps":1.2388,"marketStatus":"已收盘","marketStatusCode":5,"change":0.54,"latestTime":"06-17 15:00:00","open":22.39,"high":22.99,"low":22.37,"amount":182000000,"amplitude":0.0277,"askPrice":22.94,"askSize":69,"bidPrice":22.93,"bidSize":31,"shortable":0,"etf":0,"ttmEps":1.2388,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1718674200000},"adr":0,"adjPreClose":22.39,"symbolType":"stock","openAndCloseTimeList":[[1718587800000,1718595000000],[1718600400000,1718607600000]],"highLimit":24.63,"lowLimit":20.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":919463954,"pbRate":2.52,"roa":"--","roe":"4.67%","epsLYR":1.14,"committee":0.088751,"marketValue":21083000000,"floatMarketCap":15707000000,"peRate":18.509848,"changeRate":0.0241,"turnoverRate":0.0117,"status":0},"requestUrl":"/m/hq/s/002773/","defaultTab":"news","newsList":[{"id":"2443092425","title":"康弘药业:盐酸文拉法辛缓释片用于治疗抑郁症(包括伴有焦虑的抑郁症)及广泛性焦虑障碍","url":"https://stock-news.laohu8.com/highlight/detail?id=2443092425","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443092425?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:01","pubTimestamp":1718276498,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业06月13日在投资者关系平台上答复投资者关心的问题。公司将严格按照相关法律法规的规定和要求真实、准确、完整、及时、公平地履行信息披露义务,详细情况敬请关注公司披露的相关公告。投资者:请问公司盐酸文拉法辛缓释片在2022年和2023年的销售额为多少?盐酸文拉法辛缓释片用于治疗抑郁症及广泛性焦虑障碍。单品种销售数据涉及商业秘密,不便公开披露,敬请谅解。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300035012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","BK0196","BK0239"],"gpt_icon":0},{"id":"2441708362","title":"康弘药业(002773)6月6日主力资金净买入1206.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441708362","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441708362?lang=zh_cn&edition=full","pubTime":"2024-06-07 09:12","pubTimestamp":1717722745,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月6日收盘,康弘药业报收于23.47元,上涨3.26%,换手率3.19%,成交量21.83万手,成交额5.18亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入3929.04万元,融资偿还2597.89万元,融资净买入1331.15万元,连续3日净买入累计1823.06万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700012095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","BK0196","BK0239"],"gpt_icon":0},{"id":"2440400068","title":"康弘药业:我司KH737由于整体项目规划,目前暂无启动临床研究的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2440400068","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440400068?lang=zh_cn&edition=full","pubTime":"2024-06-04 18:04","pubTimestamp":1717495459,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)06月04日在投资者关系平台上答复投资者关心的问题。投资者:听闻KH737暂未启动临床,该管线获批临床到现在近两年时间了,是什么原因导致KH737暂未启动临床呢?康弘药业董秘:尊敬的投资者,您好!我司KH737由于整体项目规划,目前暂无启动临床研究的计划。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060400034938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0196","002773","BK0239"],"gpt_icon":0},{"id":"2440246403","title":"康弘药业(002773.SZ):普拉洛芬滴眼液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2440246403","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440246403?lang=zh_cn&edition=full","pubTime":"2024-06-03 20:00","pubTimestamp":1717416016,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)发布公告,公司于近日收到国家药品监督管理局签发的关于普拉洛芬滴眼液的《药品注册证书》(证书编号:2024S00993),批准注册。据悉,普拉洛芬滴眼液属于非甾体抗炎药,具有抑制前列腺素的生成和稳定溶酶体膜的作用,适应症为外眼及眼前节炎症的对症治疗(眼睑炎、结膜炎、角膜炎、巩膜炎、浅层巩膜炎、虹膜睫状体炎、术后炎症)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0197","BK0196","002773"],"gpt_icon":0},{"id":"2440461781","title":"康弘药业最新公告:普拉洛芬滴眼液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2440461781","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440461781?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:39","pubTimestamp":1717414787,"startTime":"0","endTime":"0","summary":"康弘药业公告,收到国家药品监督管理局签发的关于普拉洛芬滴眼液的《药品注册证书》,批准注册。适应症为外眼及眼前节炎症的对症治疗。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300025705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0197","BK0239","002773"],"gpt_icon":0},{"id":"2440469688","title":"康弘药业:截至2024年5月31日,公司股东户数为35,338户","url":"https://stock-news.laohu8.com/highlight/detail?id=2440469688","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440469688?lang=zh_cn&edition=full","pubTime":"2024-06-03 19:02","pubTimestamp":1717412531,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业06月03日在投资者关系平台上答复投资者关心的问题。投资者:请问公司截至5月31日股东户数是多少?投资者:请教公司,5月底股东人数情况。截至2024年5月31日,公司股东户数为35,338户。感谢您的关注与支持!本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300023992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0197","BK0239","002773"],"gpt_icon":0},{"id":"2439612707","title":"康弘药业:截至目前,公司尚未收到题述相关的股东动议","url":"https://stock-news.laohu8.com/highlight/detail?id=2439612707","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439612707?lang=zh_cn&edition=full","pubTime":"2024-05-30 19:01","pubTimestamp":1717066905,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)05月30日在投资者关系平台上答复投资者关心的问题。投资者:什么时候回购注销康弘药业董秘:尊敬的投资者,您好!截至目前,公司尚未收到题述相关的股东动议。如有公司回购事宜,公司将会严格恪守真实、准确、完整、及时、公平原则对相关情况予以披露。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053000033662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","BK0196","BK0239"],"gpt_icon":0},{"id":"2437499877","title":"康弘药业(002773.SZ)2023年拟每10股派3.8元 5月28日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2437499877","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437499877?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:59","pubTimestamp":1716281963,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)公告,公司2023年拟向全体股东按每10股派发现金红利3.80元(含税),本次权益分派股权登记日为2024年5月27日,除权除息日为2024年5月28日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002773","BK0197","BK0239","BK0196"],"gpt_icon":0},{"id":"2436577311","title":"华福证券:给予康弘药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2436577311","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436577311?lang=zh_cn&edition=full","pubTime":"2024-05-19 15:55","pubTimestamp":1716105322,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司盛丽华,吴沛柯近期对康弘药业进行研究并发布了研究报告《眼药龙头,眼科脑科创新药未来可期》,本报告对康弘药业给出买入评级,当前股价为22.71元。2024Q1康柏西普延续了良好的增长势头,预计全年有望保持高增长。我们判断康柏西普远期有望成为一款十亿量级的现金流品种。我们认为,公司康柏西普仍然处于快速增长期且公司创新药临床管线丰富具备差异化,首次覆盖给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051900001148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","161027"],"gpt_icon":0},{"id":"2436793750","title":"康弘药业(002773)5月16日主力资金净卖出4518.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436793750","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436793750?lang=zh_cn&edition=full","pubTime":"2024-05-17 09:22","pubTimestamp":1715908960,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月16日收盘,康弘药业报收于22.56元,下跌1.57%,换手率2.11%,成交量14.47万手,成交额3.29亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入2275.39万元,融资偿还4361.87万元,融资净偿还2086.47万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700015556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0196","002773"],"gpt_icon":0},{"id":"2435561875","title":"康弘药业(002773)5月15日主力资金净卖出6326.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435561875","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435561875?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:19","pubTimestamp":1715822346,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月15日收盘,康弘药业报收于22.92元,下跌3.33%,换手率2.09%,成交量14.3万手,成交额3.32亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入3145.72万元,融资偿还2574.62万元,融资净买入571.1万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600010137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002773","BK0197","BK0196"],"gpt_icon":0},{"id":"2435939955","title":"康弘药业:我司立他司特滴眼液正在CDE审评审批,目前审评状态正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2435939955","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435939955?lang=zh_cn&edition=full","pubTime":"2024-05-14 18:02","pubTimestamp":1715680948,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)05月14日在投资者关系平台上答复投资者关心的问题。投资者:请问立他司特滴眼液在CDE中哪个阶段了?还有多久能上市?CDE评审都有几个阶段?康弘药业董秘:尊敬的投资者,您好!我司立他司特滴眼液正在CDE审评审批,目前审评状态正常。CDE对该类事项的审评流程,您可关注现行版《药品注册管理办法》相关规定。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051400027230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0197","002773"],"gpt_icon":0},{"id":"2434064495","title":"康弘药业:公司管理层在日常经营管理中,严控信用风险,勤勉尽责","url":"https://stock-news.laohu8.com/highlight/detail?id=2434064495","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434064495?lang=zh_cn&edition=full","pubTime":"2024-05-09 18:02","pubTimestamp":1715248945,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业05月09日在投资者关系平台上答复投资者关心的问题。年报披露的其他应收款坏账准备已根据会计政策足额计提。公司将持续加强经营管理和内控建设,努力提升公司经营业绩。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900032801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0197","BK0239","002773"],"gpt_icon":0},{"id":"2433636237","title":"康弘药业(002773)5月7日主力资金净买入3552.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433636237","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433636237?lang=zh_cn&edition=full","pubTime":"2024-05-08 09:14","pubTimestamp":1715130851,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月7日收盘,康弘药业报收于23.88元,上涨4.92%,换手率3.45%,成交量23.62万手,成交额5.51亿元。近5日资金流向一览见下表:康弘药业融资融券信息显示,融资方面,当日融资买入5242.03万元,融资偿还3680.06万元,融资净买入1561.98万元,连续3日净买入累计5482.33万元。康弘药业主营业务:药品和医疗器械的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800013883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","BK0239","BK0196"],"gpt_icon":0},{"id":"2433864426","title":"康弘药业:截至2024年4月30日,公司股东户数为39,839户","url":"https://stock-news.laohu8.com/highlight/detail?id=2433864426","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433864426?lang=zh_cn&edition=full","pubTime":"2024-05-06 19:02","pubTimestamp":1714993328,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业(002773)05月06日在投资者关系平台上答复投资者关心的问题。投资者:尊敬的董秘,您好!请问公司最新的股东户数是多少?谢谢!康弘药业董秘:尊敬的投资者,您好!截至2024年4月30日,公司股东户数为39,839户。感谢您的关注与支持!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600021508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0196","002773"],"gpt_icon":0},{"id":"2431010617","title":"康弘药业(002773.SZ):KH658眼用注射液在美临床试验获美国食品药品管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2431010617","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431010617?lang=zh_cn&edition=full","pubTime":"2024-04-29 08:10","pubTimestamp":1714349456,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业 发布公告,公司子公司成都弘基生物科技有限公司于美国时间2024年4月26日收到美国食品药品管理局准许KH658眼用注射液在美国开展临床试验的邮件。据悉,KH658眼用注射液是弘基生物第二款同时获批进入中国和美国临床试验的产品,以具有自主知识产权、基于细胞特异性受体设计的新型腺相关病毒作为递送载体,具有给药方式简便、安全、转导细胞效率高的特点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","002773","BK0197","BK0196","BK1141","03347","BK1576","BK1583"],"gpt_icon":0},{"id":"2431010828","title":"康弘药业(002773.SZ):KH658眼用注射液临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2431010828","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431010828?lang=zh_cn&edition=full","pubTime":"2024-04-29 08:05","pubTimestamp":1714349120,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康弘药业(002773.SZ)发布公告,2024年4月28日,公司子公司成都弘基生物科技有限公司申报的KH658眼用注射液获得中国药品监督管理局药物临床试验批准通知书,同意开展I/II期临床试验。据悉,KH658眼用注射液是弘基生物第二款同时获批进入中国和美国临床试验的产品,以具有自主知识产权、基于细胞特异性受体设计的新型腺相关病毒作为递送载体,具有给药方式简便、安全、转导细胞效率高的特点。本品通过在人体内持续表达抗VEGF蛋白,从而抑制新生血管病变的生长,减缓疾病的进展,有望以单次给药实现患者长期获益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","BK0239","BK0197","03347","BK0196","BK1583","002773"],"gpt_icon":0},{"id":"2430219525","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升,康弘药业涨3.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430219525","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430219525?lang=zh_cn&edition=full","pubTime":"2024-04-26 13:25","pubTimestamp":1714109121,"startTime":"0","endTime":"0","summary":"04月26日,非酒精性脂肪性肝炎(NASH)概念盘中拉升,截至13点25分,非酒精性脂肪性肝炎(NASH)概念整体指数上涨2.02%,报1067.430点。从个股上来看,该概念的成分股中,康弘药业涨3.92%,通化东宝、福瑞股份、天士力涨幅居前。从资金上来看,截止发稿,非酒精性脂肪性肝炎(NASH)概念主力净流入为660.84万,其中通化东宝受到资金热捧,主力净流入4556.22万;拉长时间线来看,该板块近20日主力资金净流入-4.25亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261325217923bbc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261325217923bbc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","002773","BK0197","600867","BK0239","BK0196"],"gpt_icon":0},{"id":"2430142744","title":"4月25日康弘药业连续2日创60日新高,万家中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430142744","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430142744?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:16","pubTimestamp":1714032986,"startTime":"0","endTime":"0","summary":"证券之星消息,4月25日康弘药业涨10.00%连续2日创60日新高,收盘报20.13元,换手率4.51%,成交量30.9万手,成交额6.16亿元。重仓康弘药业的前十大公募基金请见下表:根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共12家,其中持有数量最多的公募基金为万家中证1000指数增强A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500031980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0197","399852","BK0196","BK0239","000852.SH","000001.SH","159845"],"gpt_icon":0},{"id":"2430636421","title":"4月25日康弘药业涨停分析:眼科,合成生物,创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430636421","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430636421?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:28","pubTimestamp":1714030100,"startTime":"0","endTime":"0","summary":"证券之星消息,康弘药业涨停收盘,收盘价20.13元。该股于9点42分涨停,5次打开涨停,截止收盘封单资金为3337.67万元,占其流通市值0.24%。4月25日的资金流向数据方面,主力资金净流入3968.23万元,占总成交额6.44%,游资资金净流出2841.33万元,占总成交额4.61%,散户资金净流出1126.9万元,占总成交额1.83%。近5日资金流向一览见下表:该股为眼科,合成生物,创新药概念热股,当日眼科概念上涨2.17%,合成生物概念上涨1.9%,创新药概念上涨1.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500026139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0196","BK1161","002773","BK1574","BK0239","BK0197","159992"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","stockEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":0.0267},{"period":"3month","weight":0.3107},{"period":"6month","weight":0.2777},{"period":"1year","weight":0.2208},{"period":"ytd","weight":0.2645}],"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","perCapita":"18989股","boardName":"医药制造业","registeredCapital":"91946万元","compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0438},{"period":"3month","weight":-0.0153},{"period":"6month","weight":0.0392},{"period":"1year","weight":-0.0786},{"period":"ytd","weight":0.0138}],"survey":" 成都康弘药业集团股份有限公司主营业务为药品(包括生物制品、中成药、化学药)和医疗器械(主要是眼科医疗器械)的研发、生产与销售。公司目前上市产品主要为康柏西普眼用注射液、舒肝解郁胶囊、松龄血脉康胶囊、渴络欣胶囊、胆舒胶囊、一清胶囊、盐酸文拉法辛缓释片、阿立哌唑口崩片、阿立哌唑口服溶液、枸橼酸莫沙必利片、枸橼酸莫沙必利分散片、右佐匹克隆片等药品和医疗器械。","serverTime":1718645431625,"listedPrice":13.62,"stockholders":"36074人(较上一季度增加2.08%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}